Infect Chemother.  2011 Jun;43(3):258-261. 10.3947/ic.2011.43.3.258.

Drug-Resistant Extrapulmonary Tuberculosis

• Cho OH
• Park KH
• Park SY
• Moon SM
• Chong YP
• Kim MN
• Lee SO
• Choi SH
• Woo JH
• Kim YS
• Kim SH

• KMID: 2170347
• DOI: http://doi.org/10.3947/ic.2011.43.3.258

Abstract

The prevalence and pattern of drug-resistant extrapulmonary tuberculosis (TB) is not well characterized in Korea. Therefore, we assessed the incidence of drug resistance for extrapulmonary TB in adult patients at a tertiary hospital. We retrospectively reviewed the medical records and results of drug susceptibility test in all culture-confirmed extapulmonary TB patients during an 18-month period. Out of a total of 168 cases in which the drug susceptibility test was performed, resistance to at least one anti-TB drug was found in 15 cases (8.9%), and multidrug resistance, in which TB was resistant to at least isoniazid and rifampin, was found in 3 cases (1.8%)

Keyword

Extrapulmonary; Tuberculosis; Resistance

MeSH Terms

Adult
Drug Resistance
Drug Resistance, Multiple
Humans
Incidence
Isoniazid
Korea
Medical Records
Prevalence
Retrospective Studies
Rifampin
Tertiary Care Centers
Tuberculosis
Isoniazid
Rifampin

Reference

1. Anti-tuberculous drug resistance surveillance in Korea. Korean National Tuberculosis Association. Accessed 1 February 2011. Available from: http://www.knta.or.kr/.

2. Peto HM, Pratt RH, Harrington TA, LoBue PA, Armstrong LR. Epidemiology of extrapulmonary tuberculosis in the United States, 1993-2006. Clin Infect Dis. 2009. 49:1350–1357.

3. Park WI, Kang BS, Park JS, Nam JY, Kim CS, Kim JU, Kim DY, Kim TM, Yoon SJ, Huh AJ, Yeom JS, Chang KH, Song YG, Kim JM. Clinical manifestations and diagnosis of extrapulmonary tuberculosis. Korean J Infect Dis. 2002. 34:47–54.

4. Kim SH, Choi SJ, Kim HB, Kim NJ, Oh MD, Choe KW. Diagnostic usefulness of a T-cell based assay for extrapulmonary tuberculosis. Arch Intern Med. 2007. 167:2255–2259.

5. Cho OH, Park KH, Kim T, Song EH, Jang EY, Lee EJ, Chong YP, Choi SH, Lee SO, Woo JH, Kim YS, Kim SH. Paradoxical responses in non-HIV-infected patients with peripheral lymph node tuberculosis. J Infect. 2009. 59:56–61.

6. Lin JN, Lai CH, Chen YH, Lee SS, Tsai SS, Huang CK, Chung HC, Liang SH, Lin HH. Risk factors for extra-pulmonary tuberculosis compared to pulmonary tuberculosis. Int J Tuberc Lung Dis. 2009. 13:620–625.

7. Yang Z, Kong Y, Wilson F, Foxman B, Fowler AH, Marrs CF, Cave MD, Bates JH. Identification of risk factors for extrapulmonary tuberculosis. Clin Infect Dis. 2004. 38:199–205.

8. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO/HTM/TB/2006.362. 2006. Geneva: WHO.

9. Cheng VC, Yam WC, Woo PC, Lau SK, Hung IF, Wong SP, Cheung WC, Yuen KY. Risk factors for development of paradoxical response during antituberculosis therapy in HIV-negative patients. Eur J Clin Microbiol Infect Dis. 2003. 22:597–602.

10. Song EJ, Baek DH, Jung JY, Lee SR, Lee MH, Lee SH, Lee JH, Lee KD, Lee BH, Kim SH. Paradoxical response developed during the antituberculous treatment in tuberculous pleurisy. Tuberc Respir Dis. 2008. 64:427–432.

11. Al-Majed SA. Study of paradoxical response to chemotherapy in tuberculous pleural effusion. Respir Med. 1996. 90:211–214.

12. Bai GH, Park YK, Choi YW, Bai JI, Kim HJ, Chang CL, Lee JK, Kim SJ. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. Int J Tuberc Lung Dis. 2007. 11:571–576.

13. Kim MJ, Kim HR, Hwang SS, Kim YW, Han SK, Shim YS, Yim JJ. Prevalence and its predictors of extrapulmonary involvement in patients with pulmonary tuberculosis. J Korean Med Sci. 2009. 24:237–241.

14. Kong JH, Lee SS, Kang HY, Park JS. The prevalence of initial drug resistance among pulmonary tuberculosis patients. Tuberc Respir Dis. 2008. 64:95–101.

15. Yang H, Field SK, Fisher DA, Cowie RL. Tuberculosis in Calgary, Canada, 1995-2002: site of disease and drug susceptibility. Int J Tuberc Lung Dis. 2005. 9:288–293.